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Introduction
The ability of  tumors to elicit potent tumor-rejecting immune response in syngeneic mice was demonstrated 
over 70 years ago (1–3). These studies contained the additional and then strange observation that each indi-
vidual tumor was antigenically distinct. The individuality of  tumors was confirmed in several later studies, 
often in a dramatic fashion (4, 5), suggesting the possibility that each new tumor that arose harbored a 
unique antigen. To provide a possible mechanistic basis for the existence of  an apparently limitless universe 
of  individual tumor rejection antigens, it was suggested more than 25 years ago that individual tumor-specif-
ic antigens are MHC I–presented mutant peptides (neoepitopes) that derive from random passenger muta-
tions in cancer cells (6). The earliest neoepitopes of  mouse and human cancers were defined using T cells 
as probes, and an overwhelming majority of  these neoepitopes did turn out to be mutant peptides (7–12). 
Recent genomic and bioinformatic studies have confirmed that neoepitopes derived from random passenger 
mutations in cancer cells can indeed serve as tumor rejection antigens (13–16). These studies have also shown 
clearly that only a very small proportion of  the many nonsynonymous mutations (mutations that result in 
change in an amino acid) in a tumor actually encode a tumor rejection–mediating antigen.
The rules that may be used to identify the actual tumor rejection–mediating neoepitopes (TRMNs) 
from the vast majority of  non-TRMNs (n-TRMNs) that result from the many mutations are unclear. The 
predicted binding affinity of  the mutant neoepitope peptides for the MHC alleles of  the tumor cells is often 
used as the single most important parameter to distinguish the true TRMN from the n-TRMN (14–16). 
Neoepitopes are the only truly tumor-specific antigens. Although potential neoepitopes can be 
readily identified using genomics, the neoepitopes that mediate tumor rejection constitute a 
small minority, and there is little consensus on how to identify them. Here, for the first time to 
our knowledge, we use a combination of genomics, unbiased discovery mass spectrometry 
(MS) immunopeptidomics, and targeted MS to directly identify neoepitopes that elicit actual 
tumor rejection in mice. We report that MS-identified neoepitopes are an astonishingly rich source 
of tumor rejection-mediating neoepitopes (TRMNs). MS has also demonstrated unambiguously 
the presentation by MHC I, of confirmed tumor rejection neoepitopes that bind weakly to MHC 
I; this was done using DCs exogenously loaded with long peptides containing the weakly binding 
neoepitopes. Such weakly MHC I–binding neoepitopes are routinely excluded from analysis, and 
our demonstration of their presentation, and their activity in tumor rejection, reveals a broader 
universe of tumor-rejection neoepitopes than presently imagined. Modeling studies show that a 
mutation in the active neoepitope alters its conformation such that its T cell receptor–facing surface 
is substantially altered, increasing its exposed hydrophobicity. No such changes are observed in 
the inactive neoepitope. These results broaden our understanding of antigen presentation and help 
prioritize neoepitopes for personalized cancer immunotherapy.
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However, the utility of  affinity for that purpose has been disputed in mouse (13) as well as human studies 
(17, 18). Bioinformatic data alone cannot predict which of  the many possible candidate neoepitopes will 
actually be presented by MHC proteins. Indeed, Assarsson et al. (19) showed that the proportion of  pep-
tides actually presented among all possible peptides may be on the order of  15%.
Recently, mass spectrometry (MS) has been suggested as an alternative tool that can help identify 
TRMNs. MS is the only tool that can identify the peptides that are naturally processed and presented by 
MHC molecules, albeit with limitations (20). Yadav et al. (14) demonstrated the utility of  MS in enriching 
TRMNs among a pool of  candidate neoepitopes of  a mouse carcinoma, and Gubin et al. applied targeted 
MS analysis to confirm presentation of  predicted yet confirmed immunogenic neoepitopes in a mouse 
sarcoma (15). Using clinical samples of  human melanoma, Bassani-Sternberg et al. (21) identified nearly 
100,000 peptides presented by the HLA molecules; of  those, 11 were shown to be neoepitopes, and of  the 
11, 4 elicited CD8+ T cell responses in the patient.
Mouse models allow deep mechanistic exploration through testing the ability of  large numbers of  
peptides for their ability to elicit actual tumor rejection in addition to immune responses, and to use 
this information to divine the rules of  anti-tumor immunity. In humans, such information can only be 
acquired through long clinical trials. Here, for the first time, we use a combination of  genomics, unbiased 
discovery MS immunopeptidomics, and targeted MS with labeled standards for validation to directly 
identify neoepitopes that result in actual tumor rejection and we further demonstrate the powerful poten-
tial of  MS as a screening tool. MS analysis shows here for the first time to our knowledge that peptides 
with extremely low affinity for MHC I proteins (IC50 as low as 10,000 to 40,000 nM) can be presented 
by MHC I proteins. In addition, we demonstrate the advantages provided by structural modeling, which 
provide further insight into how various mutations can act to yield potent epitopes. Our studies reveal 
unexpected nuances in our understanding of  characteristics of  TRMNs, including observations that pep-
tides that would traditionally be excluded based on predicted MHC binding and sequence characteristics 
can indeed be highly relevant. These nuances should be taken into consideration when prioritizing targets 
for personalized neoepitope-based cancer vaccines and cancer immunotherapy.
Results
Direct identification of  neoepitopes by MS-based immunopeptidomics. MS-based immunopeptidomics analysis 
was performed on MHC class I (MHC I) complexes eluted from the BALB/cJ fibrosarcoma Meth A cells 
to directly identify naturally presented neoepitopes. We searched the resulting tandem MS (MS/MS) data 
of  the eluted peptides against a reference database of  the mouse proteome concatenated to a list of  3,783 
long peptides encompassing nonsynonymous somatic mutations predicted for this tumor by our predic-
tion pipeline Consensus Caller Cross Platform (CCCP). With the data-dependent acquisition method, we 
identified a total of  6,209 MHC I–bound peptides applying an FDR of  5% for peptide identification (Sup-
plemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.129152DS1). The peptides fit the expected peptide length distribution as well as the MHC-binding 
specificities; representative results are shown for the Kd, Dd, and Ld MHC I molecules (Supplemental Fig-
ure 1, A and B). Of  the MHC I–eluted peptides identified by MS/MS, 8 were determined to be neoepi-
topes, with binding restriction to Kd or Dd MHC I molecules, as determined by the binding specificities of  
these alleles (Supplemental Figure 1B). These were independently identified in several immunopeptidomics 
experiments. The sequences of  these neoepitopes, along with their non-mutated counterparts, the predicted 
MHC I–binding affinities for cognate alleles, their Differential Agretopic Indices (DAI; ref. 13), and their 
RNA expression are shown in Table 1. The MS intensity of  the eluted neoepitopes was relatively similar to 
the intensity of  the non-mutated peptides (Supplemental Figure 1C).
Validation of  the detected neoepitopes. For validation of  the detected neoepitopes, their corresponding muta-
tions were confirmed by Sanger sequencing of  Meth A genomic DNA. In addition, we spiked synthetic 
peptide counterparts that were stably labeled with heavy isotopes (“heavy” peptides) into additional samples 
of  MHC I peptides eluted from the Meth A cells (“light” peptides). We applied the parallel reaction moni-
toring (PRM) acquisition method to target with high sensitivity and accuracy, co-eluting pairs of  heavy and 
light peptides. The data for confirmation of  2 neoepitopes, TGAARFDEF (derived from Gtf2b) and AYM-
KMLSSSL (derived from 1190007I07Rik), are shown in Figure 1; the data for the remaining 6 neoepitopes 
are shown in Supplemental Figure 2. We thus confirmed the identification of  the 8 MHC I neoepitopes. As 
a negative control, we performed a similar immunopeptidomics approach on BALB/cJ antigen-presenting 
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cells (APCs), resulting in the identification of  1,166 MHC I–binding peptides (5% FDR). None of  the neo-
epitopes were detected in the discovery or PRM MS measurements.
Tumor rejection activity of  MS-defined neoepitopes. The 8 MS-defined neoepitopes were used to immunize 
naive BALB/cJ mice twice, 1 week apart, with neoepitope-pulsed bone marrow–derived dendritic cells 
(BMDCs, 3 × 106) as adjuvants, as previously published (22). All mice were challenged with 95,000 Meth 
A tumor cells 1 week after the second immunization, and tumor growth was monitored in individual mice 
(Figure 2, A and B). Two neoepitopes, TGAARFDEF and AYMKMLSSSL, showed the highest tumor 
rejection capacities among the 8 mutant peptides tested. Mice immunized with TGAARFDEF showed 
complete tumor rejection (P < 0.0001). Among mice immunized with AYMKMLSSSL, 60% of  the immu-
nized mice were able to reject the tumor completely, and another 30% showed relatively prolonged tumor 
stabilization (P = 0.0051). Another neoepitope, IGPRAVDVL (derived from Pdpr), showed statistically sig-
nificant tumor control and an intermediate tumor rejection activity (P = 0.113). Figure 2B shows the tumor 
control indices (TCI; 23) of  the data in Figure 2A, and their statistical significance. The TCI score parame-
terizes the tumor rejection, tumor inhibition, and tumor stability scores to produce a total TCI score, which 
reflects the control of  the tumor growth in each group.
CD8 dependence of  neoepitope-elicited tumor immunity was tested in the case of  the peptide TGAARF-
DEF (derived from Gtf2b) by depletion of  neoepitope-immunized mice by anti-CD8 depleting antibody or 
an isotype control antibody during the priming phase alone, as described in the Methods. Depletion of  CD8+ 
T cells completely abolished the neoepitope-elicited tumor rejection in 3 of  the 5 mice tested (Figure 2C). 
The kinetics of  recovery of  the depleted CD8+ cells in mice is not uniform, resulting in lack of  abrogation 
of  immunity in 2 of  the 5 mice. Because depletion of  CD4+ T cells results in depletion of  helper as well as 
regulatory CD4+ T cells, and the 2 effects are contradictory, depletion of  CD4+ cells was not attempted.
In parallel, naive, non–tumor-bearing mice immunized with the neoepitopes were tested for CD8+ 
T cell responses to 7 of  the 8 neoepitopes. ELISpot assays could not be performed because of  the high 
background generated by incubation of  T cells with any DCs. CD8+ cells from mice immunized with 
individual peptides were tested for the presence of  IFN-γ+ cells; a specific response was detected in mice 
immunized with TGAARFDEF (from Gtf2b) but not with any other neoepitopes (data not shown). 
Tetramer staining was therefore used for better sensitivity and specificity (Figure 2D). (Tetramers against 
the neoepitope MAPVRTASM derived from Aebp1 gene could not be made.) Blood and the spleen of  the 
immunized mice were harvested 1 week after the second immunization and stained for CD3, CD8, as well 
as specific binding to neoepitope tetramers (Figure 2, D and E). Of  the 2 neoepitopes able to strongly elicit 
tumor rejection (TGAARFDEF and AYMKMLSSSL), only TGAARFDEF elicited a measurable CD8+ 
T cell response as detected by tetramer staining. In the blood and spleen of  TGAARFDEF-immunized 
mice, tetramer+ cells comprised approximately 0.7% and 0.43% of  the total CD8+ T cells, respectively; 
these numbers are significantly higher than the corresponding numbers in non-immunized mice (P = 
0.0068 and 0.0036 in the blood and spleen, respectively). The neoepitope AYMKMLSSSL, which elicit-
ed complete tumor rejection in 60% of  the immunized mice, did not elicit a measurable CD8+ response. 
Table 1. Characteristics of neoepitopes identified by mass spectrometry
Gene Name WT Peptide









Kd Dd Kd Dd Kd Dd
1190007I07Rik AYLKMLSSSL 35 35881 AYMKMLSSSL 22 25774 0.53 0.48 24.6 0.2774867 140.84
Prpf19 (1)D KYRQVASHVGL 189 41784 KYLQVASHVGL 40 42626 2.24 –0.02 99.4 –1.114081 143.03
Gtf2b TGAASFDEF 27859 3265 TGAARFDEF 34984 499 –0.33 2.71 51.5 1.166482 100.02
Trib3 VGPEILSSR 36942 9627 VGPEILSSL 21664 1451 0.77 2.73 168.6 –1.617108 115.78
Pdpr IGPRAVDVL 30750 237 IGPRALDVL 28208 157 0.12 0.60 19.9 –0.5142868 109.36
Aebp1 MAPVRTASL 37769 7819 MAPVRTASM 40669 13767 –0.11 –0.81 277 –0.345727 98.629
Prpf19 (2)D KYRQVASHV 22 40995 KYLQVASHV 9 41950 1.22 –0.03 99.4 –0.4623738 137.88
Snw1 SFLPAPTQL 104 41371 SFLPAPTHL 61 41697 0.77 –0.01 94.5 –1.217192 122.78
ASee the column “Mutant peptide IC50 score” for the binding allele. 
BFDR for all peptides was 1%. CTranscripts per million. DRepresent 2 neoepitopes 
from the same protein.
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The intermediate neoepitope IGPRAVDVL elicited measurable and significant CD8+ T cell response 
(~0.35% tetramer+ cells, P = 0.015). Of  the 5 MHC I neoepitopes that did not elicit tumor rejection, 2 elicit-
ed a measurable CD8+ T cell response. Of  these, the response elicited by VGPEILSSL (derived from Trib3) 
was the strongest CD8+ T cell response among all neoepitopes; approximately 10% of  the CD8+ T cells 
(in blood) in mice immunized with it were tetramer+. As controls, we measured, in 2 instances, tetramer 
response in mice immunized with an irrelevant neoepitope; such nonspecific response was never detected.
Thus, of  the 7 neoepitopes tested, 4 neoepitopes elicited expansion of  tetramer+ CD8+ T cells on immu-
nization of  naive, non–tumor-bearing mice (Figure 2E). We now examined CD8+ T cell responses to the 4 
neoepitopes in unimmunized, tumor-bearing mice (Figure 2F). Surprisingly, we could not detect a measur-
able CD8+ T cell response in tumor-bearing mice against TGAARFDEF, the neoepitope that elicited the 
strongest tumor rejection (Figure 2A) and a robust CD8+ T cell response in non–tumor–bearing immunized 
mice (Figure 2E). The neoepitope VGPEILSSL (which elicited the strongest CD8+ T cell response but 
no tumor rejection on immunization of  naive mice in Figure 2, A and E) showed significant CD8+ T cell 
response in tumor-bearing mice (Figure 2F). The neoepitope IGPRALDVL, which elicited intermediate 
tumor rejection (Figure 2A) and a good tetramer CD8+ T cell response in naive mice (Figure 2F), elic-
ited significant CD8+ T cell response in tumor-bearing mice as well (Figure 2F). Finally, the neoepitope 
KYLQVASHVGL, which did not elicit tumor rejection but elicited a strong CD8+ T cell response in naive 
Figure 1. Targeted MS–based validation of the MS-identified MHC I neoepitopes TGAARFDEF and AYMKMLSSSL. (A)  TGAARFDEF. (B) AYMKM-
LSSSL. Matched peak lists for the “heavy” and “light” ions were extracted and monitored. First, the absence of “light” peptide and the presence 
of the “heavy” peptide were confirmed by PRM as a quality control measure in the synthetic peptide samples (upper left and lower left, respec-
tively). Then, the co-elution of the synthetic “heavy” and endogenous “light” fragment ions was measured by PRM in 2 independent Meth A MHC 
I immunopeptidomics samples. Representative resulting MS/MS spectra of the “light” and “heavy” counterparts are provided. Figures were edited 
to improve resolution and readability.
 
5insight.jci.org   https://doi.org/10.1172/jci.insight.129152
R E S E A R C H  A R T I C L E
Figure 2. Tumor rejection and CD8+ tetramers elicited by immunization with neoepitopes. (A) Naive BALB/cJ mice were immunized, as described in the 
Methods, with the 8 neoepitopes identified in Table 1, and were challenged with 95,000 Meth A cells. Tumor growth was measured. Each line represents 
tumor growth in a single mouse. (B) Total TCI scores for data in A. The maximum possible TCI score is 30. Each column shows the average total TCI score 
for the indicated treatment group. Error bars are shown above each column. P values for TCI scores comparisons were calculated using 1-way ANOVA test. 
Dunnett’s test was performed as a follow-up test to ANOVA to correct for multiple comparisons. The adjusted P values are reported. The experiment was 
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mice, did not elicit such a response in tumor-bearing mice. As controls, CD8 cells from mice bearing an 
antigenically irrelevant tumor (4T1) were tested for tetramer response to all 7 neoepitopes; no response 
was detected. Altogether, CD8+ T cell responses in non-immunized tumor-bearing mice and immunized 
tumor-naive mice were often discordant.
MS analysis of  low-abundance TRMNs. In parallel with the use of  MS to identify TRMNs, we have tested a 
series of  other candidate neoepitopes (without help from MS) for tumor rejection activity. In these studies, we 
identified 2 additional TRMNs from this same tumor by applying prediction tools (13), without the aid of  MS 
(Table 2). Two neoepitopes, TYIRPFETKVK (derived from Ccdc85c) and HYLSSILRL (derived from Pacs2) 
showed the highest tumor rejection capacities (Figure 3). Mice immunized with TYIRPFETKVK showed 
almost complete tumor rejection (P = 0.0035). Among mice immunized with HYLSSILRL or SYLLGS-
GEARL (derived from Hspg2), about 50% of the immunized mice were able to reject the tumor completely 
but the activity was not significant because of  a high variation in tumor rejection. Immunity elicited by the 
TYIRPFETKVK (from Ccdc85c) was observed to be CD8 dependent by depletion assay in vivo (Figure 3C).
Based on the abundance of  RNA encoding the proteins harboring these TRMNs, these TRMNs do 
not appear to be generally abundant. Indeed, these neoepitopes could not be identified among the Meth 
A MHC I–eluted peptides identified by MS, presumably consistent with the sensitivity bias of  the MS 
approach. All but 2 of  these TRMNs have low predicted and measured affinity for MHC I molecules, 
ranging in IC50 values between 1,433 nM and 39,661 nM (Table 2). We used MS to determine whether 
these low-affinity TRMNs could be processed and presented by MHC I. Long peptides containing the 
TRMNs were pulsed on BMDCs and excess peptides were washed off. Peptides were eluted from the MHC 
I molecules purified from the pulsed DCs and were analyzed by MS. We detected a rather limited repertoire 
of  cross-presented MHC I ligands. Importantly, multiple precise TRMNs, which had been demonstrated 
experimentally to mediate tumor rejection (Supplemental Table 2), were able to be eluted from the MHC I 
of  the pulsed BMDCs (Table 2). These neoepitopes reside in genes with low-abundance transcripts (Table 
2) and could not be detected by MS among naturally presented peptides; they could only be shown to be 
presented when loaded with high amounts of  synthetic peptide on DCs. These results (a) demonstrate the 
definitive identity of  the precise neoepitope in these TRMNs, and (b) prove unequivocally that on loading, 
these TRMNs with low affinity for MHC I are nonetheless presented by MHC I molecules.
Molecular modeling of  an active and an inactive neoepitope. The activity of  TRMNs will in part be influenced 
by features that distinguish them from their WT counterparts and drive recognition by αβ T cell receptors. To 
provide insight into any such features, we modeled the structures of  the most active (TGAARFDEF) neoepi-
tope and an inactive (KYLQVASHV) neoepitope and their WT counterparts bound to the presenting MHC I.
The TRMN TGAARFDEF incorporates a serine-to-arginine mutation at P5, which is typically a sec-
ondary anchor in MHC I proteins. Phenylalanine is preferred for strong Dd-binding peptides, although 
studies have indicated that arginine, isoleucine, and glycine are also tolerated (24). Indeed, in the model of  
the TGAARFDEF/Dd complex, the mutant arginine serves as a secondary anchor, forming a salt bridge 
with Asp77 of  the Dd α1 helix (Figure 4A). In the model with the WT peptide, however, this role is played 
by the phenylalanine at P6. The switch between the use of  P6 (WT) versus P5 (neoepitope) as an anchor 
results in a large change in the conformation of  the peptide backbone from P4 to P7 (the WT and neoepi-
tope peptide backbones superimpose with a root mean square (RMS) deviation of  1.3 Å; for all common 
atoms, the value is 2.8 Å). The strain relieved by this switch can help explain the improved MHC binding 
of  the TGAARFDEF neoepitope compared with the WT peptide. Most interestingly though, the change 
in peptide conformation results in exposure of  the P5 phenylalanine, whereas the P7 aspartic acid becomes 
buried at the base of  the groove where it also interacts with the new P5 arginine. The net result is that, in 
addition to enhancing peptide binding affinity, the serine-to-arginine mutation in TGAARFDEF increases 
repeated 3 or more times. (C) BALB/cJ mice were injected with CD8-depleting antibody (or isotype control) as described in the Methods. Immunization (with 
the indicated neoepitope) and tumor challenge were as in A. P values for comparison of the AUC scores were calculated using 1-way ANOVA. Tukey’s test 
was performed as follow-up test to ANOVA to correct for multiple comparisons. The adjusted P values are reported. (D) Gating strategy for splenocytes and 
blood cells of immunized mice stained for CD3, CD8, and tetramer. (E) Naive BALB/cJ mice were immunized with each of 7 indicated neoepitopes, and blood 
and spleen of individual mice were tested for presence of tetramer+ CD8+ T cells. In most instances, the responses shown for naive mice are the averages 
of the responses in blood and spleen, which were very similar to each other. P values for CD8+ T cell response comparisons were calculated using a 2-tailed 
t test. P < 0.05 was considered statistically significant. (F) Blood and spleen of individual non-immunized tumor-bearing BALB/cJ mice were tested for the 
presence of tetramer+ CD8+ T cells for the 4 neoepitopes in E, which elicited tetramer+ CD8+ T cells in immunized tumor-naive mice. P values for CD8+ T cell 
response comparisons were calculated using a 2-tailed t test. The experiment was repeated 3 or more times.
 
7insight.jci.org   https://doi.org/10.1172/jci.insight.129152
R E S E A R C H  A R T I C L E
the exposed hydrophobic surface area of  the peptide by 25% (from 111 Å2 to 139 Å2). Notably, the exposed 
hydrophobic surface is associated with T cell receptor recognition of  antigenic epitopes (25, 26).
The inactive KYLQVASHV neoepitope incorporates an arginine-to-leucine mutation at P3. In MHC I 
complexes, the P3 side chain is typically packed against the α2 helix, as is the case in the models for both the 
neoepitope and its WT counterpart (Figure 4B). In the models, the leucine adopts the same conformation 
as the first half  of  the WT arginine side chain, but with its branched side chain packs more tightly against 
the helix. This tighter packing can explain the slightly improved Kd binding affinity of  the neoepitope com-
pared with the WT. The mutation, however, is not predicted to alter the conformation of  the peptide in any 
fashion (backbone RMS deviation of  0.4 Å). In addition, for both the neoepitope and WT peptides, the 
polar side chains at P4 (glutamine) and P7 (histidine) are predicted to face upwards toward incoming T cell 
receptors in approximately the same orientation, which might explain the lack of  anti-tumor activity of  the 
KYLQVASHV neoepitope despite the improved peptide-MHC binding affinity.
Discussion
Identification of  neoepitopes that can stimulate host immune response to cancer leading to modulation of  
the course of  tumor growth is the holy grail of  cancer immunotherapy. To the extent that these neoepitopes 
are unique to individual cancers makes the search for this holy grail that much more challenging. A given 
(mouse or human) cancer may harbor tens to hundreds of  genetic changes that may be identified using high 
throughput genomics and suitable bioinformatic approaches. An overwhelming majority of  these genetic 
changes, however, are immunologically inactive (13). Identification of  the ones that can elicit an appropri-
ate immune response and tumor rejection is a central challenge and is addressed here.
Our studies here show that MS-defined neoepitopes can be a rich source of  TRMNs. MS has been 
used previously for enrichment of  candidate TRMNs from a pool of  pre-enriched candidates identified 
by genomics in a mouse colon carcinoma (14) or for validation of  predicted neoantigens (15). Using 
clinical samples of  human melanoma, one of  us (21) identified nearly 100,000 peptides presented 
by the HLA molecules; of  those, 11 were shown to be neoepitopes, and of  the 11, 4 elicited CD8+ T 
cell response in the patient. Here, we have combined genomic analysis to identify single-nucleotide 
variants (SNVs) and have directly cross-referenced the confirmed SNVs to the MS-identified peptides 
isolated from a mouse sarcoma; we then validated the identifications with the highly sensitive and 
accurate targeted MS approach with spike-in reference peptide standards. Of  the 8 neoepitopes that 
emerged from this screening, 3 (or more than a third) were observed to be TRMNs, representing a ver-
itable shrubbery of  antigenic tumor neoepitopes. This is an extremely high yield of  TRMNs, and par-
enthetically, is surprisingly comparable with the 4 human melanoma neoepitopes (out of  11 identified 
Table 2. Low-abundance TRMNs characterized by mass spectrometry
Gene 
Name























Hspg2 SYQLGSGEA 348 SYLLGSGEA Discovery 487 2623 4 –0.48 138.6 HLVFSYLLGSGEARLVSED
Pacs2 HYLSAILRL 104 HYLSSILRL Discovery 86 41 4 0.23 28 VAGAQHYLSSILRLFVEQL




















Ccdc85c TYIRPLETKVK 616 TYIRPFETKVK PRM 1434 6155 4.2 –1.22 8.1 DPSSTYIRPFETKVKLLD
Ccdc85c YIRPLETKVK 35546 YIRPFETKVK PRM 39661 Not 
Measured
4.5 –0.16 8.1 DPSSTYIRPFETKVKLLD
ATranscripts per million.
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by MS) which were observed to elicit a CD8+ T cell response (21). None of  the TRMNs identified here 
are known driver mutations. Consistent with previous studies, they represent passenger mutations.
Examination of  the MS-identified TRMNs (Table 1 and Figure 2) and their immunological activities 
reveals several unexpected nuances. The most active TRMN, TGAARFDEF encoded in the Gtf2b gene, 
which elicits the most potent and complete tumor rejection in all mice immunized (Figure 2), has a moderate 
predicted IC50 (to D
d); peptides with this level of  moderate affinity for MHC I have been traditionally exclud-
ed as candidate MHC I–binding epitopes, including cancer neoepitopes. Of the other 2 active TRMNs, one 
(AYMKMLSSSL) has an IC50 of  22 nM (usually considered within the “acceptable” range), whereas the 
other (IGPRALDVL) with an IC50 of  greater than 150 nM, would be excluded from consideration in tra-
ditional screening of  cancer neoepitopes. Among the low-abundance TRMNs (Table 2), none have an IC50 
value of  less than 50 nM (usually considered ideal), one has an IC50 value of  less than 100 nM, one has an 
IC50 value between 100 nM and 500 nM, and all others have IC50 values that range between 1,400 nM and 
greater than 40,000 nM. By traditional criteria then, nearly all the low-abundance TRMNs (Table 2) would 
be excluded as candidate TRMNs for their low affinity, and modern predictors would exclude them for their 
low expression level. Importantly, among the 4 neoepitopes in Table 1 with an IC50 of  less than 100 nM, only 
one is a TRMN. Thus, although IC50 values are predictive of  immunogenicity (as measured by CD8
+ T cell 
responses; refs. 19, 27, 28), they are not predictors of  tumor rejection and there is a great need to improve 
prediction of  TRMNs over neoantigens with only high affinity for MHC.
The dissonance between measurable CD8+ T cell response and actual tumor rejection also becomes 
evident from the results in Figure 2. Of the 2 strong TRMNs (TGAARFDEF and AYMKMLSSSL), only 
TGAARFDEF elicited a measurable CD8+ T cell response. The neoepitope AYMKMLSSSL, which elicited 
Figure 3. Tumor rejection elicited by immunization with low-abundance TRMNs. (A) Naive BALB/cJ mice were immunized, as described in Methods, with 
the 3 neoepitopes identified in Table 2, and were challenged with 95,000 Meth A cells. Tumor growth was measured. Each line represents tumor growth in 
a single mouse. (B) Total TCI scores for data in A. Each column shows the average total TCI score for the indicated treatment group. Error bars are shown 
above each column. P values for TCI scores comparisons were calculated using 1-way ANOVA test. Dunnett’s test was performed as a follow-up test to 
ANOVA to correct for multiple comparisons. The adjusted P values are reported. The experiment was repeated 3 or more times. (C) BALB/cJ mice were 
injected with CD8-depleting antibody (or isotype control) as described in Methods. Immunization (with indicated neoepitope) and tumor challenge were 
carried out as in A. P values for comparison of the area under the curve (AUC) scores were calculated using 1-way ANOVA. Tukey’s test was performed as a 
follow-up test to ANOVA to correct for multiple comparisons. The adjusted P values are reported.
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complete tumor rejection in 60% of the immunized mice, did not elicit a measurable CD8+ T cell response. The 
intermediate neoepitope IGPRALDVL elicited measurable and significant CD8+ T cell responses. Conversely, 
of the 5 MHC I neoepitopes that did not elicit tumor rejection, 2 elicited a measurable CD8+ T cell response. 
Of these, the response elicited by VGPEILSSL was the strongest CD8+ T cell response among all neoepitopes; 
approximately 10% of the CD8+ T cells in blood in mice immunized with it were tetramer+. These observations 
clearly demonstrate that a measurable CD8+ T cell response is not a surrogate marker for tumor rejection.
CD8+ T cell responses in cancer patients are often used as surrogate markers for the activity of  neoepi-
topes, and neoantigen-specific enriched T cells adoptively transferred into patients is emerging as a promising 
new treatment modality (29). In that context, analysis of  CD8+ T cell responses to individual neoepitopes 
in tumor-bearing mice is revealing. No measurable CD8+ T cell response to TGAARFDEF (the neoepitope 
that elicited the strongest tumor rejection) was detected in tumor-bearing mice, even though this TRMN did 
elicit a robust CD8+ T cell response in non–tumor-bearing immunized mice (Figure 2D). The neoepitope 
IGPRALDVL, which elicited intermediate tumor rejection (Figure 2A) and a good CD8+ T cell response in 
naive mice (Figure 2F), elicited a significant CD8+ T cell response in tumor-bearing mice as well (Figure 2F). 
Finally, the neoepitope KYLQVASHVGL, which did not elicit tumor rejection but elicited a strong CD8+ T 
cell response in naive mice, did not elicit such response in tumor-bearing mice. Thus, measurable CD8+ T cell 
responses in tumor-bearing hosts are not predictors of  anti-tumor activity in vivo and current T cell enrich-
ment methods might miss important rejection antigens.
Discordance between CD8 responses and anti-tumor activity has been observed in many mouse (30–32) 
and human clinical studies (33–35). It is important to emphasize that even though we do not observe the 
measurable CD8 responses to be useful surrogates, the neoepitope-elicited tumor immunity is clearly CD8 
dependent (Figure 2C and Figure 3C). The most likely explanation for this apparent paradox is that the 
CD8 response to the truly effective neoepitopes is not of  a magnitude or kind that is being measured by the 
Figure 4. Models of peptide/MHC complexes indicate structural and physical correlates with immunogenicity. (A) For 
the tumor rejecting TGAARFDEF neoepitope, the serine-to-arginine substitution at position 5 is predicted to alter peptide 
conformation and increase exposed hydrophobic surface area. In the model of the wild-type complex (left panel), Phe6 
acts as a secondary anchor. Asp7 is solvent exposed, as indicated by the red surface. In the neoepitope complex (middle 
panel), the new arginine at p5 takes on the secondary anchor role, forming a salt-bridge with Asp77 of the H2-Dd α1 helix. 
The switch in secondary anchor from p6 to p5 results in Asp7 shifting down toward the base of the groove to form a 
second salt-bridge with Arg5, reducing its solvent exposure. Coincident with this shift, Phe6 moves up to become solvent 
exposed, as indicated by the green surface. An overlay of the neoepitope and its wild-type counterpart demonstrates the 
substantial differences between the two (right panel). (B) For the inactive KYLQVASHV neoepitope, the arginine-to-leu-
cine substitution at position 3 does not alter peptide conformation. In the model of the wild-type complex (left panel), 
Arg3 is positioned between the peptide backbone and the H2-Kd α2 helix. Gln4 and His7 are exposed and face up toward 
incoming TCRs. In the neoepitope complex, the new leucine at p3 simply fills the same space between the peptide and the 
α2 helix and does not introduce any structural alterations to the peptide (middle panel). An overlay of the neoepitope and 
its wild-type counterpart demonstrates the similarities between the wild-type peptide and neoepitope.
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traditional assays used for viral and high-affinity tumor epitopes but is real and functionally effective. More 
sensitive and neutral assays, such as monitoring of  T cell receptor amplification, may provide a solution.
MS analysis of  non-abundant TRMNs shows 2 significant and potentially novel aspects. The low-abun-
dance TRMNs (Table 2) are unable to be detected among naturally presented peptides, as generally expected 
because of  the reported abundance bias of  MS. However, pulsing of  DCs in vitro with long peptides con-
taining the mutant neoepitopes, coupled with MS analysis of  peptides eluted from MHC I proteins of  the 
DCs, allowed identification of  the multiple precise neoepitopes, most of  which are active in tumor rejection. 
Secondly, nearly all the low-abundance TRMNs investigated here have weak affinity for MHC I; with the 
exception of  2 peptides (which have IC50 values of  less than 500 nM), the IC50 values of  the low-abundance 
TRMNs range between 1,500 nM and greater than 40,000 nM. Peptides with such low affinities are typically 
not considered to bind sufficiently well and be presented by MHC I. We conclude that even though these 
low-abundance TRMNs have predicted low binding affinity, they were sufficiently expressed in Meth A cells, 
leading to immune recognition and destruction when challenged after immunization. MS may facilitate iden-
tification of  the minimal epitope of  such TRMNs; however, traditional predictions would not prioritize them.
Our results are based on a single model; however, they are consistent with other studies in mouse 
models and humans, even as the previous studies lack the sweep of  our current analysis. Thus, in 2 mouse 
tumors, Duan et al. reported a complete lack of  activity in several high-affinity neoepitopes, and instead, 
observed tumor rejection elicited by low-affinity neoepitopes (13). In independent human studies, Ghorani 
et al. and Rech et al. examined mutational and clinical outcome data from several thousand patients and 
concluded remarkably that the presence of  high-affinity MHC-binding neoepitopes in tumors had no cor-
relation with clinical activity (17, 18). Gross et al. had demonstrated the superior vaccination efficiency of  
low-affinity epitopes over high-affinity epitopes of  non-mutated antigens in tumor immunotherapy (36).
In addition to peptide presentation by MHC, an immunologically relevant TRMN must be recognized by 
host αβ T cell receptors. Various tolerance mechanisms protect against recognition of  self-peptides; therefore, 
active peptides must be physically distinct from their WT counterparts. Improved binding to the MHC pro-
tein through mutation, captured by the DAI score (13), can achieve this as can mutationally driven structural 
alterations that result in the presentation of  distinct peptide surfaces. However, recent work has suggested that 
certain features are preferred for efficient T cell receptor recognition; mutations that increase exposed hydro-
phobic surface or eliminate exposed charges, for example, are expected to be more strongly correlated with 
immunogenicity (25, 26). In this regard, the fact that the most protective TRMN (TGAARFDEF) identified 
incorporated a serine-to-arginine mutation in the core of  the peptide was at first puzzling. The structural mod-
eling, however, suggested that because of  large-scale structural rearrangements in response to the Ser→Arg 
mutation, exposed hydrophobic surface was increased and exposed charge was reduced. This result highlights 
the value of  incorporating structural information for assessing the potency of  candidate TRMNs.
Altogether, our studies reveal a number of  nuances to our understanding of  antigen presentation, 
including presentation of  cancer neoepitopes and TRMNs. These studies also yield precious insights on 
prioritization of  targets for personalized neoepitope-based cancer vaccines and cancer immunotherapy.
Methods
Cells. Meth A cells (1–10 × 108) and BMDCs (5 × 107 cells) were stored as dry cell pellets at −80°C until use.
Exome and RNA sequencing and bioinformatics analysis. The exome and transcriptome of  the Meth A tumor 
cell line were sequenced using both Illumina and ION Torrent sequencing platforms and putative SNVs 
were predicted using the CCCP tool from the GeNeo toolbox for genomics-guided neoepitope prediction 
available on the public Galaxy server maintained at https://neo.engr.uconn.edu. GeNeo is an expanded 
version of  the Epi-Seq pipeline previously published by our group (13). The CCCP tool calls SNVs from 
both sequencing technologies using 2 somatic variant callers, Strelka and the somatic variant caller version 
of  SNVQ (37), and generates consensus calls along with exome/RNA coverage information for each SNV 
position. The EpitopeFinder tool of  GeNeo was then used to predict MHC I binding affinities and DAI 
scores (13) for SNVs called by CCCP. The list of  long mutated peptides created by EpitopeFinder was used 
for MSMS peptide identification. Gene expression estimation from RNA-seq data was performed by using 
IsoEM2 algorithm (38). Gene expression was reported as transcripts per million (TPM) units.
Generation of  antibody-crosslinked beads. Anti–MHC I monoclonal antibody was purified from the superna-
tant of  HIB 34.1.2 (gift from Angel Miguel Garcia-Lora, Hospital Universitario Virgen de las Nieves, Grana-
da, Spain) CELLLine CL-1000 flasks (Sigma-Aldrich) using Protein A–Sepharose 4B beads (Invitrogen). 
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Antibodies were cross-linked to Protein A–Sepharose 4B beads at a concentration of  5 mg of  antibodies per 
1 mL volume of  beads. For this purpose, the antibodies were incubated with the Protein A–Sepharose 4B 
beads for 1 hour at room temperature. Chemical cross-linking was performed by the addition of  dimethyl 
pimelimidate dihydrochloride (Sigma-Aldrich) in 0.2 M sodium borate buffer pH 9 (Sigma-Aldrich) at a final 
concentration of  20 mM for 30 minutes. The reaction was quenched by incubation with 0.2 M ethanolamine 
pH 8 (Sigma-Aldrich) for 2 hours. Cross-linked antibodies were kept at 4°C until use.
Purification of  MHC I–eluted peptides. MethA cells or APCs were lysed in phosphate buffered saline 
containing 0.50% sodium deoxycholate (Sigma-Aldrich), 0.2 mM iodoacetamide (Sigma-Aldrich), 1 mM 
EDTA, 1:200 Protease Inhibitor Cocktail (Sigma-Aldrich), 1 mM phenylmethylsulfonylfluoride (Roche), 
and 1% octyl-β-D glucopyranoside (Sigma-Alrich) at 4°C for 1 hour. The lysis buffer was added to the cells at 
a concentration of  108 cells/mL. Lysates were cleared by centrifugation with a table-top centrifuge (Eppen-
dorf  Centrifuge) at 4°C at 20,000 g for 50 minutes. MHC I molecules were purified by incubating the cleared 
lysates with HIB antibodies cross-linked to Protein A–Sepharose 4B beads in affinity columns for 3 hours 
at 4°C. A ratio of  100 μL of  cross-linked beads per 108 cells was applied. The affinity columns were then 
washed as follows: 2 column volumes of  150 mM sodium chloride (NaCl; Carlo-Erba) in 20 mM Tris-HCl 
pH 8, 2 column volumes of  400 mM NaCl in 20 mM Tris-HCl pH 8, and again 2 column volumes of  150 
mM sodium chloride in 20 mM Tris-HCl pH 8. Finally, the beads were washed in 1 column volume of  20 
mM Tris-HCl pH 8. MHC complexes and the bound peptides were eluted at room temperature by adding 
twice a volume of  1% trifluoroacetic acid (TFA) equivalent to or slightly higher than the volume of  beads 
present in the column. Sep-Pak tC18 96-well plates (Waters), preconditioned with 1 mL of  80% acetonitrile 
(ACN) in 0.1% TFA and then with 2 mL of  0.1% TFA, were used for the purification and concentration 
of  MHC I peptides. Elutions containing MHC I molecules were loaded in the Sep-Pak tC18 96-well plates 
and the C18 wells were then washed with 2 mL of  0.1% TFA. The MHC I peptides were eluted with 500 
μL of  28% ACN in 0.1% TFA. MHC I peptides containing elutions were transferred into Eppendorf  tubes. 
Recovered peptides were dried using vacuum centrifugation (Thermo Fisher Scientific) and stored at −20°C.
LC-MS/MS analyses for the discovery of  neoepitopes. Prior to MS analysis, MHC I peptide samples were 
resuspended in 12 μL of  2% CH3CN and 0.1% formic acid (FA). Then, 3 μL of  sample was loaded on the 
column for each measurement by LC-MS/MS.
The LC-MS system consists of  an Easy-nLC 1200 (Thermo Fisher Scientific) coupled on-line to Q 
Exactive HF and or HF-X mass spectrometer (Thermo Fisher Scientific). Peptides were separated on a 
450-mm homemade column of  75-μm inner diameter packed with ReproSil Pur C18–AQ 1.9-μm resin (Dr. 
Maisch GmbH). The analytical separation was performed for a period of  125 minutes using a gradient of  
H2O/FA 99.9%/0.1% (solvent A) and CH3CN/FA 80%/0.1% (solvent B). The gradient was run as follows: 
0 minutes 2% B, then to 5% B at 5 minutes, 35% B at 85 minutes, 60% B at 100 minutes, 95% B at 105 min-
utes, 95% B at 110 minutes, 2% B at 115 minutes, and 2% B at 125 minutes at a flow rate of  250 nL/minute.
The mass spectrometer was operated as follows for the discovery of  neoepitopes. Full-scan MS 
spectra were acquired in the Orbitrap from m/z = 300–1,650 at a resolution of  60,000 (m/z = 200) 
with a maximum injection time of  20 ms. The auto gain control (AGC) target value was set to 3 × 106 
ions. MS/MS spectra were acquired at a resolution of  15,000 (m/z = 200) using the data-dependent 
acquisition (DDA) method on the 10 most abundant precursor ions (if  present). Each precursor ion 
was sequentially isolated with an isolation window of  1.2 m/z, activated by higher-energy collision dis-
sociation (HCD) with a normalized collision-energy (NCE) of  27. Ions were accumulated to an AGC 
target value of  1 × 105 with a maximum injection time of  120 ms. In the case of  assigned precursor ion 
charge-state of  1, and from 6 and above, no fragmentation was performed. Selected ions were dynami-
cally excluded for additional fragmentation for 20 seconds and the peptide match option was disabled. 
A few DDA analyses were also performed with an inclusion list of  selected peptides.
Identification of  peptides by MS. We employed the MaxQuant platform (39) version 1.5.5.1 to search the 
peak lists against a FASTA file containing the mouse proteome (Mus musculus_UP000000589_10090, 
the reviewed part of  UniProt, with no isoforms, including 24,907 entries downloaded in June 2016) 
concatenated to a list of  3,783 long peptides (up to 31 aa) encompassing the nonsynonymous somatic 
mutations described previously. Peptides with a length between 8 and 25 aa were allowed. The second 
peptide identification option in Andromeda was enabled. The enzyme specificity was set as unspecific. 
An FDR of  5% was required for peptides and no protein FDR was set. The initial allowed mass devia-
tion of  the precursor ion was set to 6 ppm and the maximum fragment mass deviation was set to 20 ppm. 
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Methionine oxidation and N-terminal acetylation were set as variable modifications. The peptide output 
files summarizing MaxQuant result files are provided as Supplemental Table 1. The values of  peptides 
intensities were log2 transformed and normalized. Briefly, for each sample the first, second, and third 
quartiles (q1, q2, q3) were calculated from the distribution of  all values. The median (q2) was subtracted 
from each value to center the distribution. Then we divided by the width in an asymmetric way. All val-
ues that were positive after subtraction of  the median were divided by q3 – q2, while all negative values 
were divided by q2 – q1. Average normalized intensity was calculated for each MS-detected neoepitope.
Validation of  neoepitopes with PRM. Synthetic peptides labeled with heavy isotopes were purchased 
as crude (PEPotec Immuno Custom peptide libraries grade 3) from Thermo Fisher Scientific (Paisley, 
PA49RE) with an isotopic purity greater than 99%. The labeled amino acid in each peptide is indicated in 
Supplemental Figures 2 and 3. The peptides were mixed, ensuring that each peptide was spiked into the 
MethA peptidomic samples with a concentration of  1 pmol/μL. For quality control, before spiking the 
peptides, we monitored the presence of  residual interferences of  “light” peptides by measuring separately 
each peptide with the method described in the following information. The same peptide mixture was spiked 
into the peptidomic sample eluted from the APCs as a negative control. We measured the spiked-in samples 
first with the DDA method described previously and then with the PRM method. For PRM acquisition, 
the mass spectrometer was operated at a resolution of  60,000 (at m/z = 200) for full scan MS, scanning a 
mass range from 300–1,300 m/z with a maximum ion injection time of  45 ms and an AGC target value 
of  3 × 106. Then each peptide was isolated with an isolation window of  2.0 m/z prior to ion activation by 
HCD (NCE = 27). Targeted MS/MS spectra were acquired at a resolution of  30,000 (at m/z = 200) with a 
maximum ion injection time of  60 ms and an AGC target value of  2 × 105. The data were then processed 
and analyzed by Skyline (MacCoss Lab Software) and an ion mass tolerance of  0.02 m/z was used to 
extract fragment ion chromatogram. Raw data were converted into Mascot generic format by MSConvert 
(Proteowizard) to extract matched peak lists for heavy peptide and light counterpart for visualization of  the 
MSMS spectra. The assessment of  MS/MS matching was done by pLabel (Version 2.4.0.8, pFind Studio; 
http://pfind.ict.ac.cn/software/pLabel/index.html) and Skyline.
Mice and tumors. BALB/cJ mice (6-week-old females) were purchased from the Jackson Laboratory and 
maintained in our specific pathogen–free mouse facilities under approval from the Institutional Animal Care 
and Use Committee. Meth A cells that have been in our laboratory since 1988 were originally obtained from 
Lloyd J. Old. Meth A ascites cells were used for passage. All the tested neoepitopes of  the BALB/cJ Meth A 
fibrosarcoma were synthesized by JPT Peptide Technologies GmbH and were greater than 95% pure.
BMDCs. Bone marrow cells (2–3 million per 10 cm2 bacteriological Petri dishes) of  6- to 8-week-
old mice were cultured in complete RPMI supplemented with 20 ng/mL recombinant murine granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) and incubated at 37°C for 7 days to 
generate GM-CSF BMDCs.
Immunization and tumor rejection. Day 7 BMDCs were pulsed with 40 μg of  the neoepitope (1 μL 
of  a 20 mM neoepitope solution was added to 7.5 million BMDCs in 200 μL RPMI medium for final 
peptide concentration of  100 μM). The pulsed BMDCs were washed 4 times and used to immunize a 
single mouse. Mice were randomized before being used for immunization with individual peptides to 
control for any cage effects. All immunizations were performed in the presence of  CTLA4 blockade, 
using the IgG2b isotype (clone 9D9, Bio X Cell), administered with the second immunization and every 
3 days after tumor challenge except for peptide TGAARFDEF. Tumor diameters were measured in 2 
dimensions and the average diameter determined.
TCI. TCI quantitates and integrates all 3 aspects of  tumor growth: inhibition, period of  tumor size 
stability, and tumor shrinkage (complete response), as published previously (23).
CD8 depletion in vivo. BALB/cJ mice were injected with 250 μg of  isotype control (InVivoMAb rat 
IgG2b isotype control, Bio X Cell) or CD8-depleting antibody (InVivoMAb anti–mouse CD8α, rat 
IgG2b, clone 2.43, Bio X Cell) antibodies 6 days before the first immunization (priming phase). The 
CD8+ cells remained completely depleted in all mice until day 6; after that the recovery was variable.
Flow cytometry. The antibody specific for Fixable Viability Dye eFluor 780 was purchased from eBiosci-
ence. PE tetramer specific for each neoepitope was synthesized, validated, and tested by MBL International 
Corporation. Tetramer testing was performed prior to product release according to standard operating pro-
cedures of  MBL, and the tetramers were further tested for specificity in our laboratory. The FITC-labeled 
antibody specific for CD8 (clone KT15) was purchased from the same company. BV510 CD3 (clone 17A2) 
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was purchased from Biolegend. Mouse FcR blocking reagent was purchased from Miltenyi Biotec. Flow 
cytometry was performed using Miltenyi Biotec MACSQuant analyzer. The analysis was done using FlowJo 
software (FlowJo LLC).
Structural modeling of  WT/neoepitope peptide-MHC pairs. Structural modeling of  peptide/MHC 
complexes used Rosetta (40) molecular modeling software via the PyRosetta 4.0 interface (41) and 
the ref2015 energy function (42). Template structures for modeling were chosen based on presence 
of  matching allele, peptide length, P2 anchor, and PΩ anchor, in order of  preference. The template 
for KYLQVASHV was Protein Data Bank (PDB) ID 4Z76; for TGAARFDEF it was 5KD7 (43, 44). 
For both cases, coordinates from the first molecule in the asymmetric units were used and all atoms 
from subsequent molecules were removed. Prior to modeling new peptides, the template peptide-MHC 
structures were energy minimized for 5 cycles of  the Rosetta FastRelax protocol (45), which alternates 
between energy minimization and side-chain repacking to bring structures to local energy minima.
After minimization, the desired peptide sequence was computationally introduced using the PyRo-
setta mutate_residue function to replace sequential residues in the peptide with the desired amino acid 
in the target peptide, maintaining peptide backbone atom coordinates and using idealized side-chain 
atom coordinates. This was followed by kinematic loop remodeling of  the peptide backbone via mul-
tiple cycles of  random perturbation of  the φ/ψ dihedral angles, then repacking amino acid side chains 
with the LoopMover_Perturb_KIC protocol (46) applied to a simplified centroid representation of  the 
peptide. A final high-resolution refinement of  all peptide atoms via the LoopMover_Refine_KIC proto-
col was then performed. Because of  the extensive conformational diversity allowed by stochastic mod-
eling, we generated 10,000 decoys for each peptide/MHC complex to sufficiently sample the available 
phase space. In each case, the lowest energy decoy was selected as the final model. RMS deviation of  
atomic positions of  peptide common or backbone heavy atoms between WT and mutant peptides was 
calculated, and models were inspected visually for differences in structural features using Discovery 
Studio. As expected from the stochastic modeling, the final models exhibited deviations in the peptide 
backbone from their respective template structures; in terms of  RMS deviations these were 0.47 Å for 
KYRQVASHV, 0.66 Å for KYLQVASHV, 1.42 Å for TGAASFDEF, and 0.76 Å for TGAARFDEF.
Statistics. P values were calculated using a 2-tailed t test or 1-way ANOVA test by GraphPad Prism 
5.0 (GraphPad). Dunnett’s or Tukey’s tests were performed as follow-up tests to ANOVA to correct 
for multiple comparisons for TCI and AUC comparisons, respectively. The adjusted P value for each 
comparison is reported. P < 0.05 was considered statistically significant.
Study approval. All animal studies were carried out upon under approval from the Institutional Animal 
Care and Use Committee of  the University of  Connecticut School of  Medicine.
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